Zecotek Photonics Receives Order for Its Patented Lutetium Fine Silicate Scintillation Crystals

Medical Device Investing

A U.S.-based specialized medical imaging device manufacturer has placed an order for Zecotek Photonics Inc.’s (CVE:ZMS) patented lutetium fine silicate (LFS) scintillation crystals.

A U.S.-based specialized medical imaging device manufacturer has placed an order for Zecotek Photonics Inc.’s (CVE:ZMS) patented lutetium fine silicate (LFS) scintillation crystals.
 
According to the press release:

The U.S. based company has developed a state-of-the-art molecular brain imaging device for diagnosis of Alzheimer’s disease, Frontotemporal Dementia, Lewy Body Dementia, Parkinson’s disease, and other neurological and psychiatric disorders. The U.S. based company has selected the LFS crystal for its commercial program. The initial LFS crystal order will meet the need for a single, specialized positron emission tomography (PET) medical imaging scanner which is being constructed to showcase the advanced capabilities of the new device.
“With an aging population in the United States, new state-of-the-art molecular imaging technologies will play a significant role in the research, diagnosis and treatment and of disorders of the brain,” said Dr. A.F. Zerrouk, Chairman, President, and CEO of Zecotek Photonics Inc. “Diseases of the brain touch all of us and there is significant growing demand for technology which allow scientists and medical professionals to visualize and measure brain function. There are only a few companies worldwide entering the commercialization of such imaging solutions and therefore for competitive reasons, our new partner, a leader in this growing field, will not be named at this time. We look forward to working closely with the medical imaging device manufacturer as it rolls out a new line of state-of-the-art molecular brain imaging devices.”
Molecular neuroimaging is a growing branch of medical imaging that uses technology, like positron emission tomography, to provide unprecedented views into the structure and functionality of the brain. As the worldwide geriatric population increases, the World Health Organization estimates that nearly 14% of the world population will suffer from neurologic disorders by 2020, there is a significant opportunity to expand the number of operating imaging devices across the U.S. and around the world. With the neuroimaging market currently under served, the U.S. based medical imaging device manufacturer expects to launch more than 1,000 devices over the next five years.

Click here to read the full press release.


 
The Conversation (0)
×